Recurrent or severe bacterial infection(s) in last 6 months AND Failure to respond to G-CSF treatment AND Non responsive to other immunosuppressant therapy OR Immunosuppressant therapy is contraindicated Relapse of severe autoimmune neutropenia in a patient demonstrated to have previously responded to Ig therapy Persistent severe autoimmune neutropenia AND Recurrent or severe bacterial infection(s) in last 6 Further Ig therapy will be limited to patients in months; whom a clinical response was demonstrated. AND Previous response following four weeks of Ig therapy demonstrated by improvement in neutrophil count (>0.5x10 9/L) or a reduction in infections Review periods have been considered in line Review Severe autoimmune neutropenia unresponsive to Criteria treatment with G-CSF with the literature. The initial treatment period is defined as four weeks. As this is short Review is not mandated for this condition. term treatment not requiring formal review Clinical effectiveness of Ig therapy can be demonstrated by: for re-qualification, therefore clinical outcome data have been developed rather than review Improvement in neutrophil count compared to the criteria. qualifying assessment
Recurrent or severe bacterial infection(s) in last 6 months AND Failure to respond to G-CSF treatment AND Non responsive to other immunosuppressant therapy OR Immunosuppressant therapy is contraindicated Relapse of severe autoimmune neutropenia in a patient demonstrated to have previously responded to Ig therapy Persistent severe autoimmune neutropenia AND Recurrent or severe bacterial infection(s) in last 6 months; AND Previous response following four weeks of Ig therapy demonstrated by improvement in neutrophil count (>0.5x10 9/L) or a reduction in infections Further Ig therapy will be limited to patients in whom a clinical response was demonstrated. Review Criteria Severe autoimmune neutropenia unresponsive to treatment with G-CSF Review is not mandated for this condition. Clinical effectiveness of Ig therapy can be demonstrated by: Improvement in neutrophil count compared to the qualifying assessment Review periods have been considered in line with the literature. The initial treatment period is defined as four weeks. As this is short term treatment not requiring formal review for re-qualification, therefore clinical outcome data have been developed rather than review criteria.
Autoimmune-neutropenia2017.docx